Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease

Digestive and Liver Disease

Volumn 46, Issue S5, 2014, Pages S197-S205

  Lens, Sabela ^a   Mariño, Zoe ^a   Forns, Xavier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiviral treatment; Cirrhosis; Hepatitis C; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; GRAZOPREVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PLACEBO; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; ARM; CLINICAL PRACTICE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; GRAFT RECIPIENT; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; REVIEW; THROMBOCYTE COUNT; TREATMENT DURATION; VIRAL CLEARANCE; DRUG COMBINATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; PROCEDURES;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; TRANSPLANT RECIPIENTS;

EID: 84919348848     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.10.002     Document Type: Review

References (86)

1. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1195-1206.
2. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011, 364:2405-2416.
3. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine 2011, 365:1014-1024.
4. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1207-1217.
5. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
6. Hezode C., Fontaine H., Dorival C., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. Journal of Hepatology 2013, 59:434-441.
7. Rutter K., Ferlitsch A., Maieron A., et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced disease-predictive factors for sepsis. Journal of Hepatology 2013, 58:S30.
8. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine 2013, 368:1878-1887.
9. Lawitz E., Poordad F., Brainard D.M., et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2014, [Epub ahead of print]. 10.1002/hep.27567.
10. Jacobson I.M., Dore G.J., Foster G.R., et al. Simeprevir with pegylated interferon Alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014, 384:403-413.
11. Manns M., Marcellin P., Poordad F., et al. Simeprevir with pegylated interferon Alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014, 384:414-426.
12. Jacobson I., Dore G., Foster G., et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 phase III trials. Hepatology 2013, 58(Suppl. 4):756A.
13. Forns X., Lawitz E., Zeuzem S., et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014, 146:1669-1679.
14. Zeuzem S., Berg T., Gane E., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014, 146. 430-41.e436.
15. Reddy K., Zeuzem S., Zoulim F., et al. A phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs. telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. 24th conference of the Asian Pacific Association for the Study of the Liver (APASL) 2014.
16. Hezode C., Hirschfield G.M., Ghesquiere W., et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon Alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. Hepatology 2012, 56(Suppl. 1):553A.
17. Dore G., Lawitz E., Hezode C., et al. Daclatasvir combined with peginterferon Alfa 2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 study. Journal of Hepatology 2013, 58(Suppl. 1):S570-S571.
18. Osinusi A., Meissner E.G., Lee Y.J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Journal of the American Medical Association 2013, 310:804-811.
19. Lawitz E., Ghalib R., Rodriguez-Torres M., et al. Simeprevir plus Sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (COHORT 2). Journal of Hepatology 2014, 60(Suppl. 1):S523.
20. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 2014, 370:211-221.
21. Afdhal N., Zeuzem S., Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine 2014, 370:1889-1898.
22. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine 2014, 370:1483-1493.
23. Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New England Journal of Medicine 2014, 370:1973-1982.
24. Manns M., Pol S., Jacobson I., et al. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results. Journal of Hepatology 2014, 60(Suppl. 1):S524.
25. Lawitz E., Hezode C., Gane E., et al. Efficacy and safety of MK-5172 and MK-8742±ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-WORTHY Study. Journal of Hepatology 2014, 60(Suppl. 1):S25.
26. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine 2013, 368:1867-1877.
27. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New England Journal of Medicine 2014, 370:1993-2001.
28. Pawlotsky J.M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014, 146:1176-1192.
29. Pawlotsky JM, Aghemo A, Dusheiko G, et al. EASL recommendation on treatment of hepatitis C 2014;(accessed October 2014). http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html.
30. Planas R., Balleste B., Alvarez M.A., et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology 2004, 40:823-830.
31. D'Amico G., Pasta L., Morabito A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Alimentary Pharmacology and Therapeutics 2014, 39:1180-1193.
32. Lee Y.A., Friedman S.L. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C. Antiviral Research 2014, 107:23-30.
33. Afdhal N., Everson G., Calleja J.L., et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. Journal of Hepatology 2014, 60(Suppl. 1):S28.
34. Lawitz E., Rodriguez-Torres M., Cornpropst M., et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days. Journal of Hepatology 2012, 56(Suppl. 2):S398.
35. Khatri A., Gaultier I., Menon R., et al. Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment. Hepatology 2012, 56(Suppl. 4):555A.
36. Eley T., He B., Li J., et al. Effect of hepatic impairment on the pharmacokinetics of asunaprevir (BMS-650032, ASV). Hepatology 2012, 56:1065A.
37. Ouwerkerk-Mahadevan S., Simion A., Spittaels K., et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. Abstract. Journal of Hepatology 2013, 58(Suppl. 1):S365.
38. Adam R., McMaster P., O'Grady J.G., et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transplantation 2003, 9:1231-1243.
39. Garcia-Retortillo M., Forns X., Feliu A., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35:680-687.
40. Belli L.S., Burroughs A.K., Burra P., et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transplantation 2007, 13:733-740.
41. Berenguer M., Prieto M., Rayon J.M., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000, 32(Pt 1):852-858.
42. Yilmaz N., Shiffman M.L., Stravitz R.T., et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transplantation 2007, 13:975-983.
43. Walter T., Dumortier J., Guillaud O., et al. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transplantation 2007, 13:294-301.
44. Neumann U.P., Berg T., Bahra M., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. Journal of Hepatology 2004, 41:830-836.
45. Berenguer M., Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. Journal of Hepatology 2012, 58:1028-1041.
46. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
47. Crespo G., Marino Z., Navasa M., et al. Viral hepatitis in liver transplantation. Gastroenterology 2012, 142. 1373-83.e1371.
48. Carrion J.A., Martinez-Bauer E., Crespo G., et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. Journal of Hepatology 2009, 50:719-728.
49. Forns X., Garcia-Retortillo M., Serrano T., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. Journal of Hepatology 2003, 39:389-396.
50. Everson G.T., Terrault N.A., Lok A.S., et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013, 57:1752-1762.
51. Everson G.T., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
52. Coto-Llerena M., Perez-Del-Pulgar S., Crespo G., et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. American Journal of Transplantation 2011, 11:1051-1057.
53. Verna E.C., Shetty K., Lukose T., et al. High post-transplant virologic response in hepatitis C virus infected patients treated with pre-transplant protease inhibitor-based triple therapy. Liver International 2014, [Epub ahead of print]. 10.1111/liv.12616.
54. Curry M.P., Forns X., Chung R.T., et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013, 58(Suppl. 1):314A.
55. Ferenci P., Scherzer T.M., Kerschner H., et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008, 135:1561-1567.
56. Neumann U.P., Biermer M., Eurich D., et al. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. Journal of Hepatology 2010, 52:951-952.
57. Beinhardt S., Rasoul-Rockenschaub S., Scherzer T.M., et al. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. Journal of Hepatology 2011, 54:591-592.
58. Peng C.Y., Chien R.N., Liaw Y.F. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. Journal of Hepatology 2012, 57:442-450.
59. Kim W.R., Terrault N.A., Pedersen R.A., et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137:1680-1686.
60. Poynard T., Moussalli J., Munteanu M., et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. Journal of Hepatology 2013, 59:675-683.
61. Berenguer M., Ferrell L., Watson J., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. Journal of Hepatology 2000, 32:673-684.
62. Gane E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transplantation 2008, 14(Suppl. 2):S36-S44.
63. Blasco A., Forns X., Carrion J.A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006, 43:492-499.
64. Carrion J.A., Navasa M., Bosch J., et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transplantation 2006, 12:1791-1798.
65. Berenguer M., Palau A., Aguilera V., et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. American Journal of Transplantation 2008, 8:679-687.
66. Carrion J.A., Navasa M., Garcia-Retortillo M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132:1746-1756.
67. Wang C.S., Ko H.H., Yoshida E.M., et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. American Journal of Transplantation 2006, 6:1586-1599.
68. Xirouchakis E., Triantos C., Manousou P., et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. Journal of Viral Hepatitis 2008, 15:699-709.
69. Coilly A., Roche B., Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver International 2013, 33(Suppl. 1):56-62.
70. Chalasani N., Manzarbeitia C., Ferenci P., et al. Peginterferon Alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289-298.
71. Samuel D., Bizollon T., Feray C., et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642-650.
72. Faisal N., Renner E.L., Bilodeau M., et al. Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: a Canadian multicentre experience. Hepatology 2013, 58(Suppl. 4):238A.
73. Coilly A., Roche B., Dumortier J., et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. Journal of Hepatology 2013, 60:78-86.
74. Brown K., Fontana R.J., Russo M.W., et al. Twice daily telaprevir in combination with Peginterferon Alfa 2a/Ribavirin in genotype 1 HCV liver transplant recipients: interim week 16 safety and efficacy results of HTE prospective multicentre REFRESH study. Abstract. Hepatology 2013, 58(Suppl. 1):209A.
75. Burton J.R., O'Leary J.G., Verna E.C., et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. Journal of Hepatology 2014, 10.1016/j.jhep.2014.04.037.
76. Hulskotte E., Gupta S., Xuan F., et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012, 56:1622-1630.
77. Coilly A., Furlan V., Roche B., et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrobial Agents and Chemotherapy 2012, 56:5728-5734.
78. Garg V., van Heeswijk R., Lee J.E., et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011, 54:20-27.
79. Kwo P., Mantry P., Coakley E., et al. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/r/ABT-267+ABT-333+ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. Journal of Hepatology 2014, 60(Suppl. 1):S47.
80. Mathias A., Cornpropst M., Clemons D., et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine a or tacrolimus in healthy volunteers. Hepatology 2012, 56(Suppl. 1):1063A-1064A.
81. Fontana R.J., Hughes E.A., Appelman H., et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transplantation 2012, 18:1053-1059.
82. Forns X., Samuel D., Mutimer D., et al. Interim SVR12 results from the Telaprevir phase3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection. Journal of Hepatology 2014, 60(Suppl. 1):S481.
83. Samuel D., Charlton M., Gane E., et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study. Journal of Hepatology 2014, 60(Suppl. 1):S499.
84. Forns X., Prieto M., Charlton M., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. Journal of Hepatology 2014, 60(Suppl. 1):S26.
85. Pellicelli A.M., Montalbano M., Lionetti R., et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease 2014, 46:923-927.
86. Cornpropst M., Denning J., Clemons D., et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. Journal of Hepatology 2012, 56(Suppl. 1):S433.